| Thomas P Short, MD | |
|
119 Longwood Drive, Huntsville, AL 35801 | |
| (256) 533-6488 | |
| (256) 533-6495 |
| Full Name | Thomas P Short |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 40 Years |
| Location | 119 Longwood Drive, Huntsville, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144219148 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 00026848 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Decatur Morgan Hospital - Decatur Campus | Decatur, AL | Hospital |
| Huntsville Hospital | Huntsville, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Decatur Digestive Diseases Pc | 4385618784 | 4 |
News Archive
Today's early morning highlights from the major news organizations, including reports on the least expensive health insurance markets and efforts to set up skimpier plans under the health law.
By blocking a protein, VDAC1, in the insulin-producing beta cells, it is possible to restore their normal function in case of type 2 diabetes. In preclinical experiments, the researchers behind a new study have also shown that it is possible to prevent the development of the disease.
Clostridium difficile infection (CDI) is a significant and growing problem in hospitals and other health care facilities, but no new drugs to treat the condition have been developed in several decades. However, a large-scale, phase 3 trial conducted by Canadian and U.S. researchers shows that the new antibiotic Fidaxomicin is superior to existing treatments, demonstrating a 45 percent reduction in recurrences vs. the existing licensed treatment.
Warren Kindzierski, University of Alberta researcher in the School of Public Health, says people living in the communities of Fort McMurray, Fort Mckay and Fort Chipewyan should feel confident that the air they are breathing is safe.
› Verified 1 days ago
| Entity Name | Decatur Digestive Diseases Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245313519 PECOS PAC ID: 4385618784 Enrollment ID: O20040823000306 |
News Archive
Today's early morning highlights from the major news organizations, including reports on the least expensive health insurance markets and efforts to set up skimpier plans under the health law.
By blocking a protein, VDAC1, in the insulin-producing beta cells, it is possible to restore their normal function in case of type 2 diabetes. In preclinical experiments, the researchers behind a new study have also shown that it is possible to prevent the development of the disease.
Clostridium difficile infection (CDI) is a significant and growing problem in hospitals and other health care facilities, but no new drugs to treat the condition have been developed in several decades. However, a large-scale, phase 3 trial conducted by Canadian and U.S. researchers shows that the new antibiotic Fidaxomicin is superior to existing treatments, demonstrating a 45 percent reduction in recurrences vs. the existing licensed treatment.
Warren Kindzierski, University of Alberta researcher in the School of Public Health, says people living in the communities of Fort McMurray, Fort Mckay and Fort Chipewyan should feel confident that the air they are breathing is safe.
› Verified 1 days ago
| Entity Name | Riverside Gastroenterology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669762480 PECOS PAC ID: 3476730409 Enrollment ID: O20110531000514 |
News Archive
Today's early morning highlights from the major news organizations, including reports on the least expensive health insurance markets and efforts to set up skimpier plans under the health law.
By blocking a protein, VDAC1, in the insulin-producing beta cells, it is possible to restore their normal function in case of type 2 diabetes. In preclinical experiments, the researchers behind a new study have also shown that it is possible to prevent the development of the disease.
Clostridium difficile infection (CDI) is a significant and growing problem in hospitals and other health care facilities, but no new drugs to treat the condition have been developed in several decades. However, a large-scale, phase 3 trial conducted by Canadian and U.S. researchers shows that the new antibiotic Fidaxomicin is superior to existing treatments, demonstrating a 45 percent reduction in recurrences vs. the existing licensed treatment.
Warren Kindzierski, University of Alberta researcher in the School of Public Health, says people living in the communities of Fort McMurray, Fort Mckay and Fort Chipewyan should feel confident that the air they are breathing is safe.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas P Short, MD Po Box 2324, Birmingham, AL 35201-2324 Ph: (256) 533-6488 | Thomas P Short, MD 119 Longwood Drive, Huntsville, AL 35801 Ph: (256) 533-6488 |
News Archive
Today's early morning highlights from the major news organizations, including reports on the least expensive health insurance markets and efforts to set up skimpier plans under the health law.
By blocking a protein, VDAC1, in the insulin-producing beta cells, it is possible to restore their normal function in case of type 2 diabetes. In preclinical experiments, the researchers behind a new study have also shown that it is possible to prevent the development of the disease.
Clostridium difficile infection (CDI) is a significant and growing problem in hospitals and other health care facilities, but no new drugs to treat the condition have been developed in several decades. However, a large-scale, phase 3 trial conducted by Canadian and U.S. researchers shows that the new antibiotic Fidaxomicin is superior to existing treatments, demonstrating a 45 percent reduction in recurrences vs. the existing licensed treatment.
Warren Kindzierski, University of Alberta researcher in the School of Public Health, says people living in the communities of Fort McMurray, Fort Mckay and Fort Chipewyan should feel confident that the air they are breathing is safe.
› Verified 1 days ago
Dr. Ankur Jindal, M.D Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 201 Sivley Rd Sw, Suite 440, Huntsville, AL 35801 Phone: 256-265-0780 Fax: 256-265-0781 | |
Dr. Michael Frederick Donze Jr., D.O. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 101 Sivley Rd Sw, Huntsville, AL 35801 Phone: 256-801-6047 | |
Tarun Kukkadapu, MBBS Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1104 Monroe St Sw, Huntsville, AL 35801 Phone: 256-265-5864 Fax: 256-265-5865 | |
Jennifer L. Kiessling, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 4601 Whitesburg Dr Se, Suite 201, Huntsville, AL 35802 Phone: 256-880-1050 Fax: 256-213-4681 | |
Zaid Al-rufaye, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 301 Governors Dr Sw Rm 396, Huntsville, AL 35801 Phone: 256-551-4652 | |
Mr. Jesse Dewayne Faulk, Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 301 Governors Dr Sw, Huntsville, AL 35801 Phone: 256-536-5511 | |
Rami Hawari, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 420 Lowell Dr Se, Suite 204, Huntsville, AL 35801 Phone: 256-536-9031 Fax: 256-539-4240 |